An official website of the United States government Here's how you know

The .gov means it's official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Drugs@FDA: FDA-Approved Drugs

Home | Previous Page

New Drug Application (NDA): 201699
Company: CUBIST PHARMS LLC

Summary Review

Products on NDA 201699

Drug Name	Active Ingredients	Strength	Dosage Form/Route	Marketing Status	TE Code	RLD	RS
DIFICID	FIDAXOMICIN	200MG	TABLET;ORAL	Prescription	AB	Yes	Yes

Approval Date(s) and History, Letters, Labels, Reviews for NDA 201699

Original Approvals or Tentative Approvals

Action Date	Submission	Action Type	Submission Classification	Review Priority; Orphan Status	Letters, Reviews, Labels, Patient Package Insert	Notes	Url
05/27/2011	ORIG-1	Approval	Type 1 - New Molecular Entity	PRIORITY	Label (PDF) Letter (PDF) Review Summary Review (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/201699s000lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2011/201699s000ltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/201699Orig1s000TOC.cfm https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/201699Orig1s000SumR.pdf

Supplements

Action Date	Submission	Supplement Categories or Approval Type	Letters, Reviews, Labels, Patient Package Insert	Note	Url
05/28/2020	SUPPL-13	Labeling-Container/Carton Labels, Labeling-Package Insert	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/201699s013,213138s001lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2020/201699Orig1s013,213138Orig1s001ltr.pdf
01/24/2020	SUPPL-12	Efficacy-New Patient Population	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/201699s012lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2020/201699Orig1s012ltr.pdf
04/05/2019	SUPPL-11	Labeling-Patient Package Insert, Labeling-Package Insert	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201699s011lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/201699Orig1s011ltr.pdf
03/15/2019	SUPPL-10	Labeling-Package Insert, Labeling-Package Insert	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201699s010lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/201699Orig1s010ltr.pdf
02/24/2015	SUPPL-9	Efficacy-Pediatric	Letter (PDF)	Label is not available on this site.	https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2015/201699Orig1s009ltr.pdf
11/18/2013	SUPPL-7	Manufacturing (CMC)		Label is not available on this site.
06/06/2013	SUPPL-6	Manufacturing (CMC)		Label is not available on this site.
02/21/2013	SUPPL-5	Manufacturing (CMC)		Label is not available on this site.
04/04/2013	SUPPL-4	Labeling-Package Insert	Label (PDF) Letter (PDF)	Please see www.fda.gov/STIC for labeling requirements on susceptibility test interpretive criteria for systemic antibacterial and antifungal drugs.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/201699s004lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2013/201699Orig1s004ltr_corrected.pdf
12/19/2012	SUPPL-3	Manufacturing (CMC)		Label is not available on this site.

Labels for NDA 201699

Action Date	Submission	Supplement Categories or Approval Type	Letters, Reviews, Labels, Patient Package Insert	Note	Url
05/28/2020	SUPPL-13	Labeling-Container/Carton Labels	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/201699s013,213138s001lbl.pdf
05/28/2020	SUPPL-13	Labeling-Package Insert	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/201699s013,213138s001lbl.pdf
01/24/2020	SUPPL-12	Efficacy-New Patient Population	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/201699s012lbl.pdf
04/05/2019	SUPPL-11	Labeling-Patient Package Insert	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201699s011lbl.pdf
04/05/2019	SUPPL-11	Labeling-Package Insert	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201699s011lbl.pdf
03/15/2019	SUPPL-10	Labeling-Package Insert	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201699s010lbl.pdf
03/15/2019	SUPPL-10	Labeling-Package Insert	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201699s010lbl.pdf
04/04/2013	SUPPL-4	Labeling-Package Insert	Label (PDF)	Please see www.fda.gov/STIC for labeling requirements on susceptibility test interpretive criteria for systemic antibacterial and antifungal drugs.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/201699s004lbl.pdf
05/27/2011	ORIG-1	Approval	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/201699s000lbl.pdf

Therapeutic Equivalents for NDA 201699

DIFICID

TABLET;ORAL; 200MG
TE Code = AB

Drug Name	Active Ingredients	Strength	Dosage Form/Route	Marketing Status	RLD	TE Code	Application No.	Company
DIFICID	FIDAXOMICIN	200MG	TABLET;ORAL	Prescription	Yes	AB	201699	CUBIST PHARMS LLC
FIDAXOMICIN	FIDAXOMICIN	200MG	TABLET;ORAL	Prescription	No	AB	208443	ACTAVIS LABS FL

Top